Compound Planning Inc. Sells 12,200 Shares of Novo Nordisk A/S $NVO

Compound Planning Inc. lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 40.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,137 shares of the company’s stock after selling 12,200 shares during the period. Compound Planning Inc.’s holdings in Novo Nordisk A/S were worth $667,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. Scarborough Advisors LLC acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth about $26,000. WealthCollab LLC lifted its position in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. Finally, Maseco LLP acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on NVO. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. HSBC reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Five research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Trading Up 1.8%

Novo Nordisk A/S stock opened at $49.63 on Tuesday. The business has a 50 day moving average price of $46.46 and a two-hundred day moving average price of $45.63. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market cap of $221.58 billion, a price-to-earnings ratio of 11.65, a price-to-earnings-growth ratio of 4.45 and a beta of 0.77. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.28.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.